HC Wainwright Has Bullish Estimate for INO FY2024 Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Inovio Pharmaceuticals in a research note issued to investors on Monday, January 13th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings per share of ($4.19) for the year, up from their previous estimate of ($4.39). HC Wainwright has a “Neutral” rating and a $3.00 price target on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q4 2024 earnings at ($0.87) EPS, Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($2.41) EPS.

A number of other analysts have also issued reports on INO. Oppenheimer decreased their price objective on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research note on Monday, November 18th. JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of Inovio Pharmaceuticals in a report on Friday, January 10th. Finally, Royal Bank of Canada cut their price objective on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Friday, November 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $12.40.

Inovio Pharmaceuticals Price Performance

NASDAQ:INO opened at $1.87 on Wednesday. Inovio Pharmaceuticals has a 1 year low of $1.74 and a 1 year high of $14.75. The stock’s fifty day moving average price is $3.27 and its two-hundred day moving average price is $6.00. The company has a market cap of $48.81 million, a P/E ratio of -0.90 and a beta of 0.84.

Institutional Trading of Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of INO. Geode Capital Management LLC grew its holdings in shares of Inovio Pharmaceuticals by 6.7% during the third quarter. Geode Capital Management LLC now owns 621,631 shares of the biopharmaceutical company’s stock worth $3,594,000 after purchasing an additional 38,833 shares in the last quarter. Barclays PLC lifted its position in Inovio Pharmaceuticals by 282.6% during the third quarter. Barclays PLC now owns 34,003 shares of the biopharmaceutical company’s stock valued at $197,000 after purchasing an additional 25,116 shares during the last quarter. FMR LLC grew its stake in Inovio Pharmaceuticals by 370.1% in the 3rd quarter. FMR LLC now owns 27,261 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 21,462 shares in the last quarter. State Street Corp increased its holdings in shares of Inovio Pharmaceuticals by 11.7% in the 3rd quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock worth $2,836,000 after buying an additional 51,414 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Inovio Pharmaceuticals by 62.2% in the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 12,100 shares during the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.